EX-99.1 2 v164049_ex99-1.htm Unassociated Document
Exhibit 99.1


FOR INFORMATION CONTACT:
Elisha Finney (650) 424-6803
elisha.finney@varian.com

Spencer Sias (650) 424-5782
spencer.sias@varian.com

For Immediate Release:

Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2009

Net earnings per diluted share from continuing operations rise 15 percent; reach $0.78 for the quarter and $2.65 for fiscal year 2009

PALO ALTO, Calif., Oct. 29, 2009 – Varian Medical Systems (NYSE:VAR) today is reporting net earnings from continuing operations of $0.78 per diluted share in the fourth quarter of fiscal year 2009, up 15 percent from $0.68 in the year-ago quarter.  Net earnings per diluted share from continuing operations for the full fiscal year 2009 climbed to $2.65, also up 15 percent from $2.31 in fiscal year 2008.  The sale of the non-proton therapy portion of the ACCEL business earlier in the year and its resulting classification as a discontinued operation reduced net earnings per diluted share by $0.01 to $0.77 for the quarter and by $0.10 to $2.55 for the fiscal year.

Compared to the same periods in fiscal year 2008, fourth-quarter revenues grew 8 percent to $642 million and revenues for the full fiscal year 2009 rose by 7 percent to $2.2 billion.  Net orders, including a large proton system order, rose 4 percent for the quarter to $755 million and increased 3 percent for the fiscal year to $2.4 billion.  The fiscal 2009 year-ending backlog increased to $2.1 billion, up 9 percent from the prior year. Excluding the proton therapy order, the backlog was up 5 percent.

“Our company has encountered a challenging business environment in North America, but we achieved excellent earnings growth for the quarter and the fiscal year as a result of mix shifts towards newer higher margin oncology products and services as well as successful ongoing initiatives to cut costs,” said Tim Guertin, president and CEO of Varian Medical Systems.  “Our Oncology Systems and X-Ray Products businesses each contributed to solid revenue growth for the quarter versus strong year-ago comparisons.  Net orders increased with the help of the company’s first proton therapy system order and continued demand for oncology products in international markets.”

The company ended the fiscal year with $554 million in cash and cash equivalents and $37 million of debt. During the fourth quarter, the company spent $30 million to repurchase 700,000 shares of common stock.  Throughout the fiscal year, the company spent $101 million to repurchase 2.2 million shares, which helped to reduce average diluted shares outstanding by 2.6 million from the prior year to 125 million. The company ended the quarter with accounts receivable days sales outstanding of 81, an increase of seven days from the year-ago quarter, but down two days from the third quarter of fiscal year 2009.
 
-- more --
 
Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2009
Page 2
 
Oncology Systems
Oncology Systems’ fourth quarter revenues in fiscal year 2009 totaled $527 million, up 9 percent from the same period last fiscal year.  Oncology revenues for the fiscal year were $1.8 billion, up 8 percent from the fiscal year 2008 total.

Fourth-quarter net orders were $570 million, down 7 percent with a 20 percent decline in North America and 12 percent growth in international markets.  Net orders for the fiscal year rose to $1.9 billion, up 1 percent from last year, with a 7 percent decline in North America and 11 percent growth in international markets.

 “Our Oncology Systems business is weathering a climate of uncertainty in North America created by economic recession as well as the prospects of healthcare reform and reimbursement cuts,” Guertin said.  “Meanwhile, we have had a healthy year in the international oncology market.  Oncology Systems achieved solid revenue growth and improved its margins through increased sales of software and services.”

X-Ray Products
Fourth quarter revenues for the X-Ray Products business were $93 million, up 11 percent from the year-ago quarter, and revenues for the full fiscal year were $332 million, up 9 percent from fiscal year 2008 levels.  Compared to corresponding periods in fiscal year 2008, X-Ray Products’ fourth quarter net orders rose 3 percent to $97 million, and fiscal year net orders rose 1 percent to $339 million.

“X-Ray Products orders and sales grew with the help of demand for its new line of radiographic imaging panels,” Guertin said.  “Aftermarket X-ray tubes also contributed to growth in orders and revenues for this segment.  A strong focus on cost control led to higher operating earnings for this business.”

Other
The company’s Other category, which is comprised of the Security and Inspection Products business, the Varian Particle Therapy business, and the Ginzton Technology Center, recorded fourth quarter revenues of $23 million, down 16 percent from the year-ago period.  Revenues for the fiscal year totaled $85 million, down 9 percent from fiscal year 2008, principally as a result of slower deployment of security systems.

Fourth-quarter net orders in the Other category were $89 million, up $68 million from the year-ago quarter with strong contributions from the particle therapy and security businesses.  As previously announced, the company was awarded a $62 million contract by Skandion Kliniken following a public tender to deliver the equipment for Sweden’s first proton therapy system.  “As is common in these public tenders, this award is being challenged by a competitor in Swedish courts, we believe that the award was proper and we booked the order during the fourth quarter,” Guertin said.  Including this order, fiscal year 2009 net orders for the Other category totaled $151 million, up $56 million from the fiscal year 2008 total.

-- more –
 
Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2009
Page 3

Outlook
“Weak orders in the second half of fiscal year 2009 together with ongoing uncertainty stemming from the recession, the healthcare reform movement and proposed cuts in reimbursements in North America give us a cautious outlook for fiscal year 2010,” said Guertin.  “We believe that for the first quarter of fiscal year 2010 total company revenues could increase by three to four percent over the prior year.  Including a higher tax rate and a one-time $0.02-per-share charge for a recently completed reduction in force, net earnings per diluted share from continuing operations for the first quarter could be in the range of $0.52 to $0.56.  For the full fiscal year 2010, we estimate that revenues and operating earnings could increase by four to five percent over the fiscal year 2009 total and that net earnings per diluted share from continuing operations could be in the range of $2.65 to $2.75.”

Investor Conference Call
Varian Medical Systems is scheduled to conduct its fiscal year 2009 conference call at 2 p.m. PT today.  To hear a live webcast or replay of the call, visit the investor relations page on the company’s web site at www.varian.com/investor where it will be archived for a year.  To access the call via telephone, dial 1-866-700-6067 from inside the U.S. or 1- 617-213-8834 from outside the U.S. and enter confirmation code 74581862.  The replay can be accessed by dialing 1-888-286-8010 from inside the U.S or 1-617-801-6888 from outside the U.S. and entering confirmation code 40919568.  The telephone replay will be available through 5 p.m. PT, October 30, 2009.

#  #  #

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, Europe, and China and approximately 79 sales and support offices around the world. For more information, visit http://www.varian.com.
 
 
Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company’s future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as RapidArc, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms “expect,” “could,” “believe,” “estimate,” “outlook,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company’s actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of economic conditions, including the current global recession; the impact of health care reforms, and/or changes in third-party reimbursement levels; credit availability for capital expenditures for cancer care; currency exchange rates and tax rates; demand for the company’s products; the company’s ability to develop and commercialize new products; the company’s reliance on sole or limited-source suppliers; the impact of reduced or limited demand by sole purchasers of certain X-ray tubes; the company’s ability to maintain or increase operating margins; the impact of competitive products and pricing; the company’s ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; the ability to make strategic acquisitions and to successfully integrate the acquired operations into the company’s business; the company’s ability to protect the company’s intellectual property; the potential loss of key distributors or key personnel; challenges to public tender awards; and the other risks listed from time to time in the company’s filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
 
A summary of earnings and other financial information follows.
 
Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2009
Page 4
 
Varian Medical Systems, Inc. and Subsidiaries
 Condensed Consolidated Statements of Earnings
 (Unaudited)
 
 
(Dollars and shares in millions, except per share amounts)
  
Q4 QTR
2009
  
Q4 QTR
2008
  
Q4 YTD
2009
  
Q4 YTD
2008
  
                     
 
Net orders
$
755.3
  
725.3
  
2,380.6
  
2,302.1
  
 
Oncology Systems
  
569.6
  
610.5
  
1,890.7
  
1,870.7
  
 
X-Ray Products
  
97.0
  
94.2
  
339.1
  
336.8
  
 
Other
  
88.7
  
20.6
  
150.8
  
94.6
  
                     
 
Order backlog
$
2,054.4
  
1,887.8
  
2,054.4
  
1,887.8
  
                     
 
Revenues
$
642.0
  
592.7
  
2,214.1
  
2,069.7
  
 
Oncology Systems
  
526.8
  
482.6
  
1,797.8
  
1,671.8
  
 
X-Ray Products
  
92.6
  
83.1
  
331.7
  
305.2
  
 
Other
  
22.6
  
27.0
  
84.6
  
92.7
  
                     
 
Cost of revenues
$
357.1
  
330.2
  
1,253.6
  
1,192.2
  
                     
 
Gross margin
  
284.9
  
262.5
  
960.5
  
877.5
  
 
As a percent of revenues
  
  44.4%
  
44.3%
  
43.4%
  
42.4%
  
                     
 
Operating expenses
                  
 
Research and development
  
38.1
  
39.1
  
147.4
  
135.6
  
 
Selling, general and administrative
  
96.2
  
87.8
  
339.0
  
322.5
  
                     
 
Operating earnings
  
150.6
  
135.6
  
474.1
  
419.4
  
 
As a percent of revenues
  
23.5%
  
22.9%
  
21.4%
  
20.3%
  
                     
 
Interest income/(expense), net
  
(0.2)
  
2.2
  
0.5
  
6.6
  
                     
 
Earnings from continuing operations before taxes
  
150.4
  
137.8
  
474.6
  
426.0
  
                     
 
Taxes on earnings
  
53.2
  
50.7
  
143.1
  
130.7
  
                     
 
Earnings from continuing operations
  
97.2
  
87.1
  
331.5
  
295.3
  
 
As a percent of revenues
  
15.1%
  
14.7%
  
15.0%
  
14.3%
  
                     
 
Loss  from discontinued operations – net of  taxes  (1)
  
(0.2)
  
(8.6)
  
(12.5)
  
(15.8)
  
                     
 
Net earnings
$
97.0
  
78.5
  
319.0
  
279.5
  
                     
 
Net earnings (loss) per share – basic:
                  
 
Continuing operations
$
0.78
  
0.70
  
2.67
  
2.37
  
 
Discontinued operations  (1)
  
-
  
(0.07)
  
(0.10)
  
(0.13)
  
 
Net earnings per share
$
0.78
  
0.63
  
2.57
  
2.24
  
                     
 
Net earnings (loss)  per share – diluted:
                  
 
Continuing operations
$
0.78
  
0.68
  
2.65
  
2.31
  
 
Discontinued operations  (1)
  
(0.01)
  
(0.06)
  
(0.10)
  
(0.12)
  
 
Net earnings per share
$
0.77
  
0.62
  
2.55
  
2.19
  
                     
 
Shares used in the calculation of net earnings per share:  
                  
 
Average shares outstanding - basic
  
124.3
  
124.5
  
124.0
  
124.8
  
 
Average shares outstanding - diluted
  
125.3
  
127.4
  
125.0
  
127.6
  
                     
 
(1) The operating results of ACCEL research instruments are classified as discontinued operations for all periods presented.
 
Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2009
Page 5
 
Varian Medical Systems, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
             
(In thousands)
  
October 2,
2009
    
September 26,
2008 (2)
  
   
(Unaudited)
        
Assets
            
Current assets
            
Cash and cash equivalents
   $ 553,529     $ 397,306  
Accounts receivable, net
     580,918       486,310  
Inventories
     321,861       282,980  
Deferred tax assets and other
     216,143       209,006  
Current assets of discontinued operations (1)
     -       18,799  
Total current assets
     1,672,451       1,394,401  
                 
Property, plant and equipment
     527,135       452,576  
Accumulated depreciation and amortization
     (263,075 )     (234,393 )
Property, plant and equipment, net
     264,060       218,183  
                 
Goodwill
     210,346       209,146  
Other assets
     161,391       150,694  
Long term assets of discontinued operations (1)
     -       3,088  
Total assets
   $ 2,308,248     $ 1,975,512  
                 
Liabilities and Stockholders’ Equity
                
Current liabilities
                
Accounts payable
   $ 116,093     $ 105,281  
Accrued expenses
     304,402       252,915  
Deferred revenues
     130,588       141,368  
Advance payments from customers
     226,964       201,783  
Product warranty
     50,823       51,141  
Short-term borrowings
     4,445       -  
Current maturities of long-term debt
     9,005       7,987  
Current liabilities of discontinued operations (1)
     -       21,202  
Total current liabilities
     842,320       781,677  
Other long-term liabilities
     130,751       134,251  
Long-term debt
     23,394       32,399  
Total liabilities
     996,465       948,327  
                 
Stockholders’ Equity
                
Common stock
     125,281       125,590  
Capital in excess of par value
     516,478       468,384  
Retained earnings and accumulated other comprehensive loss
     670,024       433,211  
Total stockholders’ equity
     1,311,783       1,027,185  
Total liabilities and stockholders’ equity
   $ 2,308,248     $ 1,975,512  
   
(1)  The assets and liabilities of ACCEL research instruments are classified as discontinued operations.
(2)  The condensed consolidated balance sheet as of September 26, 2008 was derived from audited financial statements as of  that date.